Citadel Advisors
AVTX icon

Citadel Advisors’s Avalo Therapeutics AVTX Stock Holding History

Citadel Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$997K Buy
+66,800
New +$1.04M ﹤0.01% 7656

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citadel Advisors's AVTX Position: Q1 2026 in Review

Citadel Advisors reduced its Avalo Therapeutics (AVTX) stake by 54% in Q1 2026, selling an estimated $3.53M and leaving 193,735 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #5337.

Citadel Advisors first reported a position in AVTX in Q4 2015 and has held it in 16 quarters since. The position peaked at $7.62M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Citadel Advisors held 193,735 shares of Avalo Therapeutics worth $2.89M as of Q1 2026.
  • Citadel Advisors sold 225,756 Avalo Therapeutics shares in Q1 2026, an estimated $3.53M.
  • Avalo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5337 holding.
  • Citadel Advisors first reported a position in Avalo Therapeutics in Q4 2015 and has held it in 16 quarters since.
  • Citadel Advisors's Avalo Therapeutics position peaked at $7.62M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.